Cepheid is a molecular diagnostics company that develops, manufactures, and markets integrated systems for testing in the clinical and non-clinical markets. Its solutions enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company primarily offers a GeneXpert System that integrates sample preparation in addition to DNA amplification and detection. The company also provides a SmartCycler System that integrates DNA amplification and detection to allow the analysis of a sample and Xpert tests for use on the GeneXpert System.

Employee Rating

4More
TypeSubsidiary
Parent CompanyDanaher
HQSunnyvale, CA, US
Founded1996
Websitecepheid.com
Cybersecurity ratingBMore
Cepheid was founded in 1996 and is headquartered in Sunnyvale, CA, US

Viewing summary data as a guest

Sign up for free to see all data
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Cepheid

John Bishop

John Bishop

Chairman & CEO
Annamaria Vaszko

Annamaria Vaszko

Vice President, FP&A
Show more

Cepheid Office Locations

Cepheid has offices in Sunnyvale, Geel, São Paulo, Shanghai and in 11 other locations
Sunnyvale, CA, US (HQ)
Building 1, 904 E Caribbean Dr
Geel, BE
Kleinhoefstraat 5 bus 26
São Paulo, BR
R. Luigi Galvani, 200 - 51 - Itaim Bibi
Shanghai, CN
Fu Quan Bei Lu, Changning Qu
Maurens-Scopont, FR
Vira Solelh
Krefeld, DE
Europark Fichtenhain A 4
Show all (15)

Cepheid Financials and Metrics

Summary Metrics

Founding Date

1996

Total Funding

$8.1 m

Investors

In total, Cepheid had raised $8.1 m. Cepheid is a subsidiary of Danaher

Cepheid Revenue

Cepheid's revenue was reported to be $538.58 m in FY, 2015 which is a 15% increase from the previous period.
Annual
USDFY, 2015

Revenue

538.6m

Revenue growth, %

15%

Cost of goods sold

269.9m

Gross profit

268.7m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016

Revenue

144.8m146.0m158.5m

Cost of goods sold

72.6m73.2m83.4m

Gross profit

72.2m72.8m75.1m

Gross profit Margin, %

50%50%47%
Annual
USDFY, 2015

Cash

112.6m

Accounts Receivable

66.6m

Prepaid Expenses

18.5m

Inventories

148.7m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016

Cash

89.8m100.3m115.7m

Accounts Receivable

72.6m62.8m81.9m

Prepaid Expenses

26.6m23.4m23.1m

Inventories

150.4m156.8m155.7m
Annual
USDFY, 2015

Net Income

(48.5m)

Depreciation and Amortization

33.5m

Inventories

(15.1m)

Accounts Payable

4.2m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016

Net Income

(6.6m)(16.8m)(27.7m)

Depreciation and Amortization

9.0m18.2m28.4m

Inventories

(1.7m)(8.1m)(7.2m)

Accounts Payable

(1.4m)6.0m3.9m
USDFY, 2015

Revenue/Employee

316.8k

Debt/Equity

0.8 x

Debt/Assets

0.4 x

Financial Leverage

2.2 x
Show all financial metrics

Cepheid Operating Metrics

Jun, 2021Oct, 2021

Patent Applications (US)

101102

Patents (US)

128132

Trademark Applications (US)

2

Trademarks (US)

212
Show all operating metrics

Cepheid Acquisitions / Subsidiaries

Company NameDateDeal Size
Cepheid AB
Cepheid Benelux
Cepheid Diagnostics (Shanghai) Co., Ltd.
CEPHEID EUROPE
CEPHEID HBDC
CEPHEID LIMITED
Cepheid Switzerland GmbH
CEPHEID UK LIMITED
SEFID RUS, OOO

Cepheid Revenue Breakdown

Embed Graph

Cepheid revenue breakdown by business segment: 5.3% from Non-Clinical, 79.3% from Clinical Reagents and 15.4% from Clinical Systems

Cepheid revenue breakdown by geographic segment: 41.0% from International and 59.0% from North America

Cepheid Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Cepheid Online and Social Media Presence

Embed Graph

Cepheid Company Culture

  • Overall Culture

    B

    70/100

  • CEO Rating

    D+

    62/100

  • Compensation

    D+

    57/100

  • Diversity

    D+

    60/100

Learn more on Comparably

Cepheid News and Updates

Insights on the Human Papillomavirus Testing Global Market to 2026 - Featuring Arbor Vita, Breakspear Medical and Cepheid Among Others

Dublin, Oct. 08, 2021 (GLOBE NEWSWIRE) -- The "Human Papillomavirus Testing Market Research Report by Product, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering. The Global Human Papillomavirus Testing Market size was es…

Cepheid Announces Direct Commercial Operations in Canada

Today, Cepheid announced the launch of direct commercial operations in Canada. Cepheid Canada's operations will include direct service, order management, and technical support.

Cepheid Receives Emergency Use Authorization for Xpert Xpress CoV-2/Flu/RSV plus

SUNNYVALE, Calif., Sept. 14, 2021 /PRNewswire/ -- Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert Xpress CoV-2/Flu/RSV plus, a rapid molecular diagnostic test for qualitative detection of the viruses...

Cepheid Receives Emergency Use Authorization for Xpert Xpress CoV - 2 / Flu / RSV plus

Cepheid Receives Emergency Use Authorization for Xpert Xpress CoV - 2 / Flu / RSV plus

Cepheid Receives Emergency Use Authorization for Xpert Xpress CoV-2/Flu/RSV plus

Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert Xpress CoV-2/Flu/RSV plus, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and respiratory syncytial virus…

Oncology Molecular Diagnostics Market - Remain Positive On Improving Demand Outlook : Abbott Laboratories , Bayer Healthcare , Beckton Dickinson , Cepheid

Oncology Molecular Diagnostics Market - Remain Positive On Improving Demand Outlook : Abbott Laboratories , Bayer Healthcare , Beckton Dickinson , Cepheid
Show more

Cepheid Blogs

Cepheid Receives Health Canada License for SARS-CoV-2, Flu A, Flu B and RSV Combination Test

Challenged by Similar Clinical Presentations, Accurate Detection & Differentiation of all 4 Viruses is Critical for Clinicians This Flu Season

Cepheid Receives Emergency Use Authorization For SARS-CoV-2, Flu A, Flu B and RSV Combination Test

Challenged by Similar Clinical Presentations, Accurate Detection & Differentiation of all 4 Viruses is Critical for Clinicians This Flu Season

Cepheid Receives FDA Clearance for Xpert® BCR-ABL Ultra Test

Enabling on-demand monitoring of BCR-ABL levels in patients with Chronic Myeloid Leukemia (CML) SUNNYVALE, CALIF. — Oct. 2, 2019 —  Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration for Xpert BCR-ABL Ultra for monitoring disease burden in patients with…
Show more

Cepheid Frequently Asked Questions

  • When was Cepheid founded?

    Cepheid was founded in 1996.

  • Who are Cepheid key executives?

    Cepheid's key executives are John Bishop and Annamaria Vaszko.

  • How many employees does Cepheid have?

    Cepheid has 4,070 employees.

  • What is Cepheid revenue?

    Latest Cepheid annual revenue is $538.6 m.

  • What is Cepheid revenue per employee?

    Latest Cepheid revenue per employee is $132.3 k.

  • Who are Cepheid competitors?

    Competitors of Cepheid include Luminex, OncoCell MDx and HEALTH Gene Technologies.

  • Where is Cepheid headquarters?

    Cepheid headquarters is located at Building 1, 904 E Caribbean Dr, Sunnyvale.

  • Where are Cepheid offices?

    Cepheid has offices in Sunnyvale, Geel, São Paulo, Shanghai and in 11 other locations.

  • How many offices does Cepheid have?

    Cepheid has 15 offices.